GMTX News and Press, Gemini Therapeutics Inc. From 10/19/21

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced Chief Medical Officer, Samuel Barone, M.D., will present virtually at the 2 nd Annua...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of inducement awards under Gemini’s 2021 Inducement Plan to two new emp...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced a corporate restructuring, including several executive officer transitions, to p...

Lightstone Ventures Raises $375 Million Fund Fund III will continue firm's work partnering with entrepreneurs developing breakthrough therapies and medical technologies Christina Isacson, Ph.D., joins as Partner and Young Kwon, Ph.D., as Operating Partner PR Newswire ...

- Studies show mechanism of action and biodistribution of GEM103 and support continued development as a potential treatment for AMD Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined ...

- Study shows well-tolerated safety profile with no increased risk of CNV, complement regulation, reduction in inflammatory state and supports bi-monthly dosing Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatm...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to par...

- GEM103 biological activity in intraocular compartment showed ability of potential first in class complement regulator to inhibit C3 activation and amplification - GEM103 continues to be well tolerated and intraocular pharmacokinetics support advancing program to late-stage, ...

The following slide deck was published by Gemini Therapeutics, Inc. in conjunction with this event. For further details see: Gemini Therapeutics (GMTX) Investor Presentation - Slideshow

- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV - Completed enrollment in Phase 2a study of GEM103 in wet AMD with six-month ...